24
Views
4
CrossRef citations to date
0
Altmetric
Review

Long-term social costs of hypertension

&
Pages 33-40 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Thomas Philipp, Robert D. Glazer, Yanxing Zhao & Rainer Pospiech. (2009) Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. Current Medical Research and Opinion 25:1, pages 187-193.
Read now

Articles from other publishers (3)

Chanhyun Park, Jing Fang, Nikki A. Hawkins & Guijing Wang. (2017) Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults. American Journal of Preventive Medicine 53:6, pages S172-S181.
Crossref
Liyuan Ma, Wen Wang, Yong Zhao, Yuqing Zhang, Qing Deng, Mingbo Liu, Hui Sun, Jianchun Wang & Lisheng Liu. (2012) Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive Patients. American Journal Cardiovascular Drugs 12:2, pages 137-142.
Crossref
Beth L. Greene, Jeffrey D. Miller, T Michelle Brown, Robert S. Harshman, Gerald T. Richerson & Joseph J. Doyle. (2009) Economic Impact of the BP DownShift Program on Blood Pressure Control Among Commercial Driver License Employees. Journal of Occupational & Environmental Medicine 51:5, pages 542-553.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.